Tumor-unrelated CD4 T cell help augments CD134 plus CD137 dual costimulation tumor therapy

Journal of Immunology

Volumn 195, Issue 12, 2015, Pages 5816-5826

  Mittal, Payal ^a   Rose, Marie Clare St ^a,b   Wang, Xi ^a   Ryan, Joseph M ^a   Wasser, Jeffrey S ^a   Vella, Anthony T ^a   Adler, Adam J ^a,c  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; EPITOPE; GRANZYME B; TRANSCRIPTION FACTOR FOXP3; CYTOKINE;

ARTICLE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FLOW CYTOMETRY; HELPER CELL; HUMAN; MELANOMA; PRIORITY JOURNAL; T CELL DEPLETION; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; C57BL MOUSE; CELL DIFFERENTIATION; CELL LINE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; SKIN TUMOR; TRANSGENIC MOUSE; TUMOR ESCAPE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD137; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR CROSS-TALK; RECEPTORS, OX40; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE;

EID: 84983094244     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502032     Document Type: Article

References (58)

1. Pardoll, D. M., and S. L. Topalian. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10: 588-594.
2. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
3. Mumberg, D., P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96: 8633-8638.
4. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
5. Nesbeth, Y. C., D. G. Martinez, S. Toraya, U. K. Scarlett, J. R. Cubillos-Ruiz, M. R. Rutkowski, and J. R. Conejo-Garcia. 2010. CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. J. Immunol. 184: 5654-5662.
6. Quezada, S. A., T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, et al. 2010. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
7. Xie, Y., A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, and P. A. Antony. 2010. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
8. Bevan, M. J. 2004. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 4: 595-602.
9. Ossendorp, F., E. Mengedé, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702.
10. Marzo, A. L., B. F. Kinnear, R. A. Lake, J. J. Frelinger, E. J. Collins, B. W. S. Robinson, and B. Scott. 2000. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
11. Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
12. Schietinger, A., M. Philip, R. B. Liu, K. Schreiber, and H. Schreiber. 2010. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J. Exp. Med. 207: 2469-2477.
13. Bos, R., and L. A. Sherman. 2010. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70: 8368-8377.
14. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
15. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191: 1221-1232.
16. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
17. Drake, C. G., A. D. Doody, M. A. Mihalyo, C. T. Huang, E. Kelleher, S. Ravi, E. L. Hipkiss, D. B. Flies, E. P. Kennedy, M. Long, et al. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7: 239-249.
18. Dudley, M. E., C. A. Gross, R. P. Somerville, Y. Hong, N. P. Schaub, S. F. Rosati, D. E. White, D. Nathan, N. P. Restifo, S. M. Steinberg, et al. 2013. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31: 2152-2159.
19. Slingluff, C. L., Jr., G. Yamshchikov, P. Neese, H. Galavotti, S. Eastham, V. H. Engelhard, D. Kittlesen, D. Deacon, S. Hibbitts, W. W. Grosh, et al. 2001. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7: 3012-3024.
20. Ridge, J. P., F. Di Rosa, and P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474-478.
21. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
22. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
23. Yee, C., J. A. Thompson, D. Byrd, S. R. Riddell, P. Roche, E. Celis, and P. D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
24. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repop-ulation with antitumor lymphocytes. Science 298: 850-854.
25. Gottschalk, S., C. Y. Ng, M. Perez, C. A. Smith, C. Sample, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2001. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-843.
26. Schmollinger, J. C., R. H. Vonderheide, K. M. Hoar, B. Maecker, J. L. Schultze, F. S. Hodi, R. J. Soiffer, K. Jung, M. J. Kuroda, N. L. Letvin, et al. 2003. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 100: 3398-3403.
27. Castle, J. C., S. Kreiter, J. Diekmann, M. Löwer, N. van de Roemer, J. de Graaf, A. Selmi, M. Diken, S. Boegel, C. Paret, et al. 2012. Exploiting the mutanome for tumor vaccination. Cancer Res. 72: 1081-1091.
28. Duan, F., J. Duitama, S. Al Seesi, C. M. Ayres, S. A. Corcelli, A. P. Pawashe, T. Blanchard, D. McMahon, J. Sidney, A. Sette, et al. 2014. Genomic and bio-informatic profiling of mutational neoepitopes reveals new rules to predict an-ticancer immunogenicity. J. Exp. Med. 211: 2231-2248.
29. Uno, T., K. Takeda, Y. Kojima, H. Yoshizawa, H. Akiba, R. S. Mittler, F. Gejyo, K. Okumura, H. Yagita, and M. J. Smyth. 2006. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12: 693-698.
30. Lee, S. J., L. Myers, G. Muralimohan, J. Dai, Y. Qiao, Z. Li, R. S. Mittler, and A. T. Vella. 2004. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 173: 3002-3012.
31. Lee, S. J., R. J. Rossi, S. K. Lee, M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella. 2007. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. J. Immunol. 179: 2203-2214.
32. Cuadros, C., A. L. Dominguez, P. L. Lollini, M. Croft, R. S. Mittler, P. Borgström, and J. Lustgarten. 2005. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int. J. Cancer 116: 934-943.
33. Gray, J. C., R. R. French, S. James, A. Al-Shamkhani, P. W. Johnson, and M. J. Glennie. 2008. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur. J. Immunol. 38: 2499-2511.
34. Qui, H. Z., A. T. Hagymasi, S. Bandyopadhyay, M. C. St Rose, R. Ramanarasimhaiah, A. Ménoret, R. S. Mittler, S. M. Gordon, S. L. Reiner, A. T. Vella, and A. J. Adler. 2011. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J. Immunol. 187: 3555-3564.
35. Bandyopadhyay, S., M. Long, H. Z. Qui, A. T. Hagymasi, A. M. Slaiby, M. A. Mihalyo, H. L. Aguila, R. S. Mittler, A. T. Vella, and A. J. Adler. 2008. Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J. Immunol. 181: 7728-7737.
36. St Rose, M. C., R. A. Taylor, S. Bandyopadhyay, H. Z. Qui, A. T. Hagymasi, A. T. Vella, and A. J. Adler. 2013. CD134/CD137 dual costimulation-elicited IFN-g maximizes effector T-cell function but limits Treg expansion. Immunol. Cell Biol. 91: 173-183.
37. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
38. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, and W. R. Heath. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188: 409-414.
39. Spiotto, M. T., P. Yu, D. A. Rowley, M. I. Nishimura, S. C. Meredith, T. F. Gajewski, Y. X. Fu, and H. Schreiber. 2002. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17: 737-747.
40. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34.
41. Grubin, C. E., S. Kovats, P. deRoos, and A. Y. Rudensky. 1997. Deficient positive selection of CD4 T cells in mice displaying altered repertoires of MHC class II-bound self-peptides. Immunity 7: 197-208.
42. Pippig, S. D., C. Pen-a-Rossi, J. Long, W. R. Godfrey, D. J. Fowell, S. L. Reiner, M. L. Birkeland, R. M. Locksley, A. N. Barclay, and N. Killeen. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163: 6520-6529.
43. Duan, F., S. Simeone, R. Wu, J. Grady, I. Mandoiu, and P. K. Srivastava. 2012. Area under the curve as a tool to measure kinetics of tumor growth in experimental animals. J. Immunol. Methods 382: 224-228.
44. Hsieh, C. S., S. E. Macatonia, A. O'Garra, and K. M. Murphy. 1995. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181: 713-721.
45. Bulliard, Y., R. Jolicoeur, J. Zhang, G. Dranoff, N. S. Wilson, and J. L. Brogdon. 2014. OX40 engagement depletes intratumoral Tregs via activating FcgRs, leading to antitumor efficacy. Immunol. Cell Biol. 92: 475-480.
46. Dawicki, W., E. M. Bertram, A. H. Sharpe, and T. H. Watts. 2004. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J. Immunol. 173: 5944-5951.
47. Ngoi, S. M., M. C. St Rose, A. M. Menoret, D. E. Smith, M. G. Tovey, A. J. Adler, and A. T. Vella. 2012. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc. Natl. Acad. Sci. USA 109: 10486-10491.
48. Zanetti, M. 2005. T for two: when helpers need help. Autoimmun. Rev. 4: 571-578.
49. Zhou, L., M. M. Chong, and D. R. Littman. 2009. Plasticity of CD4+ T cell lineage differentiation. Immunity 30: 646-655.
50. Sharma, M. D., D. Y. Hou, B. Baban, P. A. Koni, Y. He, P. R. Chandler, B. R. Blazar, A. L. Mellor, and D. H. Munn. 2010. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33: 942-954.
51. Takeda, I., S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura, and N. Ishii. 2004. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172: 3580-3589.
52. Vu, M. D., X. Xiao, W. Gao, N. Degauque, M. Chen, A. Kroemer, N. Killeen, N. Ishii, and X. C. Li. 2007. OX40 costimulation turns off Foxp3+ Tregs. Blood 110: 2501-2510.
53. Pearce, E. L., A. C. Mullen, G. A. Martins, C. M. Krawczyk, A. S. Hutchins, V. P. Zediak, M. Banica, C. B. DiCioccio, D. A. Gross, C. A. Mao, et al. 2003. Control of effector CD8+ T cell function by the transcription factor Eomeso-dermin. Science 302: 1041-1043.
54. Kwon, B. 2012. Regulation of Inflammation by Bidirectional Signaling through CD137 and Its Ligand. Immune Netw. 12: 176-180.
55. Zhang, P., F. Gao, Q. Wang, X. Wang, F. Zhu, C. Ma, W. Sun, and L. Zhang. 2007. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand. J. Immunol. 66: 435-440.
56. Melero, I., J. V. Johnston, W. W. Shufford, R. S. Mittler, and L. Chen. 1998. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190: 167-172.
57. Weinberg, A. D., N. P. Morris, M. Kovacsovics-Bankowski, W. J. Urba, and B. D. Curti. 2011. Science gone translational: the OX40 agonist story. Immunol. Rev. 244: 218-231.
58. Ascierto, P. A., E. Simeone, M. Sznol, Y. X. Fu, and I. Melero. 2010. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37: 508-516.